Healthcare provider profile · identity verified

Sergio Mercado, MD

Allopathic & Osteopathic Physicians|Family Medicine · LEESBURG, FL · NPI 1730123902

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sergio Mercado, MD received $72.92 in general payments during 2025 across 3 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 40.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$72.92

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$29.32	40.2%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$24.48	33.6%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$19.12	26.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$72.92	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$29.32	1	2025
Source payment records 2025-05-14 · Boehringer Ingelheim Pharmaceuticals, Inc. · $29.32 · Open Payments source
VYNDAQEL Normalized: vyndaqel	Drug	PFIZER INC.	$24.48	1	2025
Source payment records 2025-12-11 · PFIZER INC. · $24.48 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$19.12	1	2025
Source payment records 2025-01-06 · ABBVIE INC. · $19.12 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	62	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	62	17
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	165	41

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	818	248
Amlodipine Besylate	Amlodipine Besylate	565	186
Levothyroxine Sodium	Levothyroxine Sodium	515	159
Lisinopril	Lisinopril	467	166
Potassium Chloride	Potassium Chloride	407	64
Losartan Potassium	Losartan Potassium	386	144
Gabapentin	Gabapentin	375	99
Furosemide	Furosemide	347	85
Omeprazole	Omeprazole	346	104
Metoprolol Succinate	Metoprolol Succinate	334	92
Metoprolol Tartrate	Metoprolol Tartrate	328	81
Pantoprazole Sodium	Pantoprazole Sodium	312	86
Donepezil Hcl	Donepezil Hcl	308	59
Rosuvastatin Calcium	Rosuvastatin Calcium	285	117
Tamsulosin Hcl	Tamsulosin Hcl	282	79
Simvastatin	Simvastatin	262	67
Metformin Hcl	Metformin Hcl	261	110
Trazodone Hcl	Trazodone Hcl	254	49
Memantine Hcl	Memantine Hcl	241	40
Quetiapine Fumarate	Quetiapine Fumarate	238	34
Sertraline Hcl	Sertraline Hcl	227	64
Pravastatin Sodium	Pravastatin Sodium	198	85
Famotidine	Famotidine	183	45
Ezetimibe	Ezetimibe	169	67
Eliquis	Apixaban	165	41
Xarelto	Rivaroxaban	164	23
Carvedilol	Carvedilol	161	43
Escitalopram Oxalate	Escitalopram Oxalate	160	35
Mirtazapine	Mirtazapine	152	29
Clopidogrel	Clopidogrel Bisulfate	146	53
Carbidopa-Levodopa	Carbidopa/Levodopa	145	17
Bumetanide	Bumetanide	133	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	133	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	128	40
Hydrochlorothiazide	Hydrochlorothiazide	123	66
Risperidone	Risperidone	119	12
Levetiracetam	Levetiracetam	116	19
Divalproex Sodium	Divalproex Sodium	113	14
Duloxetine Hcl	Duloxetine Hcl	113	31
Alendronate Sodium	Alendronate Sodium	112	39
Albuterol Sulfate Hfa	Albuterol Sulfate	107	66
Lamotrigine	Lamotrigine	101	11
Spironolactone	Spironolactone	101	22
Allopurinol	Allopurinol	95	33
Citalopram Hbr	Citalopram Hydrobromide	93	21
Prednisone	Prednisone	91	49
Meloxicam	Meloxicam	86	42
Finasteride	Finasteride	76	22
Januvia	Sitagliptin Phosphate	73	23
Celecoxib	Celecoxib	72	24
Pioglitazone Hcl	Pioglitazone Hcl	68	37
Alprazolam	Alprazolam	67	37
Montelukast Sodium	Montelukast Sodium	67	25
Digoxin	Digoxin	65	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	65	34
Venlafaxine Hcl Er	Venlafaxine Hcl	65	11
Triamcinolone Acetonide	Triamcinolone Acetonide	63	39
Jardiance	Empagliflozin	62	17
Olanzapine	Olanzapine	62	suppressed
Glipizide	Glipizide	61	25
Hydralazine Hcl	Hydralazine Hcl	61	18
Fluticasone Propionate	Fluticasone Propionate	59	39
Zolpidem Tartrate	Zolpidem Tartrate	58	35
Valsartan	Valsartan	57	14
Atenolol	Atenolol	54	18
Tramadol Hcl	Tramadol Hcl	54	32
Farxiga	Dapagliflozin Propanediol	53	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	35
Fluoxetine Hcl	Fluoxetine Hcl	51	20
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	50	27
Irbesartan	Irbesartan	48	27
Lactulose	Lactulose	46	11
Midodrine Hcl	Midodrine Hcl	46	suppressed
Galantamine Hbr	Galantamine Hbr	45	suppressed
Raloxifene Hcl	Raloxifene Hcl	45	suppressed
Warfarin Sodium	Warfarin Sodium	44	19
Oxybutynin Chloride Er	Oxybutynin Chloride	42	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	41	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	40	19
Ketoconazole	Ketoconazole	40	27
Ondansetron Hcl	Ondansetron Hcl	40	15
Propranolol Hcl	Propranolol Hcl	40	13
Lovastatin	Lovastatin	39	suppressed
Glimepiride	Glimepiride	38	21
Nifedipine Er	Nifedipine	38	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	38	12
Rivastigmine	Rivastigmine Tartrate	38	suppressed
Pregabalin	Pregabalin	37	21
Baclofen	Baclofen	36	suppressed
Calcitriol	Calcitriol	36	suppressed
Azithromycin	Azithromycin	35	27
Clonidine Hcl	Clonidine Hcl	35	suppressed
Methylprednisolone	Methylprednisolone	35	32
Amiodarone Hcl	Amiodarone Hcl	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	12
Wixela Inhub	Fluticasone Propion/Salmeterol	34	16
Diltiazem Hcl	Diltiazem Hcl	33	suppressed
Myrbetriq	Mirabegron	33	suppressed
Buspirone Hcl	Buspirone Hcl	31	12
Cephalexin	Cephalexin	31	22
Solifenacin Succinate	Solifenacin Succinate	31	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Lorazepam	Lorazepam	30	13
Cefuroxime	Cefuroxime Axetil	29	27
Meclizine Hcl	Meclizine Hcl	29	14
Clonazepam	Clonazepam	28	15
Latanoprost	Latanoprost	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	11
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Oxycodone Hcl	Oxycodone Hcl	26	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Divalproex Sodium Er	Divalproex Sodium	24	suppressed
Amoxicillin	Amoxicillin	22	21
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Ozempic	Semaglutide	22	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Bupropion Hcl	Bupropion Hcl	20	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	20	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	20	suppressed
Topiramate	Topiramate	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	14
Fenofibrate	Fenofibrate	19	11
Ibuprofen	Ibuprofen	19	11
Jantoven	Warfarin Sodium	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	18
Fluconazole	Fluconazole	18	suppressed
Memantine Hcl Er	Memantine Hcl	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	12
Diltiazem 12hr Er	Diltiazem Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Loperamide	Loperamide Hcl	17	suppressed
Methenamine Hippurate	Methenamine Hippurate	17	suppressed
Metolazone	Metolazone	17	suppressed
Nystatin	Nystatin	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	17	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	16	15
Fludrocortisone Acetate	Fludrocortisone Acetate	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	11
Methotrexate	Methotrexate Sodium	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	13
Zonisamide	Zonisamide	16	suppressed
Ertapenem	Ertapenem Sodium	15	suppressed
Fenofibrate	Fenofibrate,micronized	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Primidone	Primidone	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	13
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Torsemide	Torsemide	14	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Dalfampridine Er	Dalfampridine	13	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	13	suppressed
Heparin Sodium	Heparin Sodium,porcine	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Methimazole	Methimazole	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Mupirocin	Mupirocin	13	12
Nitroglycerin	Nitroglycerin	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	13	suppressed
Ursodiol	Ursodiol	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	12	suppressed
Guanfacine Hcl	Guanfacine Hcl	12	suppressed
Ingrezza	Valbenazine Tosylate	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Naltrexone Hcl	Naltrexone Hcl	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Pentoxifylline	Pentoxifylline	12	suppressed
Sotalol	Sotalol Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Xifaxan	Rifaximin	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Linzess	Linaclotide	11	suppressed
Procto-Med Hc	Hydrocortisone	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$72.92 · 3 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE, VRAYLAR, VYNDAQEL	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error